Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2018 08:05 ET | Source: Avid Bioservices, Inc

Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab

TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an...
September 07, 2017 08:10 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma

TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
September 06, 2017 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017

TUSTIN, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
July 14, 2017 16:13 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments

-- Avid Achieves Year-Over-Year Topline Revenue Growth of 30% Exceeding $57 Million -- -- Recent Presentation Supports Bavituximab’s Potential to Improve Clinical Outcome for Immune Checkpoint...
July 07, 2017 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017

TUSTIN, Calif., July 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...
June 06, 2017 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock

TUSTIN, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
April 04, 2017 08:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy

-- SUNRISE Data Analysis Demonstrates Statistically Significant Overall Survival (OS) Improvement in Patients Receiving Bavituximab plus Docetaxel and Subsequent Immunotherapy Compared to Placebo plus...
April 03, 2017 08:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities

-- Latest Findings from Ongoing Collaboration with Memorial Sloan Kettering (MSK) Support Potential Applications for Combining CAR T and Anti-PS in Treatment of Solid Tumors -- TUSTIN, Calif., April ...
March 13, 2017 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments

-- Avid Revenue Guidance Increased to $60 - $65 Million for Full FY 2017 and Contracted Backlog of Future Business Currently at $70 Million ---- Multiple Preclinical Studies Demonstrating...
March 09, 2017 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

TUSTIN, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...

Next Page keyboard_arrow_right